Patients older than 50 years, without any significant environmental or occupational exposures and without evidence of any underlying autoimmune disease are very likely to have IPF if the HRCT is felt ...

Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines ...

Rein Therapeutics initiates RENEW phase 2 trial of LTI-03 in patients with idiopathic pulmonary fibrosis: Austin, Texas Tuesday, May 13, 2025, 18:00 Hrs [IST] Rein Therapeutics (R ...

Pulmonary fibrosis (PF) is a progressive interstitial lung disease (ILD) characterized by excessive fibrotic tissue deposition in the pulmonary parenchyma. The term "pulmonary" refers to the lungs, ...

The RENEW Phase 2 trial will enroll up to 120 IPF patients with topline data expected in the first half of 2026 In the previously reported Phase 1b study, LTI-03 showed ...